Clinical trials are how we discover which healthcare methods are the best for patients. Here, a sample of the population suffering from a particular ailment are used to test treatments. Through such evaluation, researchers can test the efficacy of new medications, treatment methods and so on. Traditionally, clinical trials were relegated to a brick and mortar test site. However, this has proved to be a limitation. As such, Curebase has taken the bull by the horns with its innovative decentralized clinical trial (DCT) method, which not only speeds up the clinical trial process, but is also more patient centric than traditional methods.
20 Things You Didn’t Know About Curebase
Curebase was established in 2017 by founder and CEO, Tom Lemberg. The mission of Curebase is to streamline clinical trials by utilizing modern technology. As such, the decentralized clinical trial method was developed. By creating a patient-centric clinical trial method which centered on the development of virtual clinical trials. Their method allowed clinical trials to grant opportunities for patients who resided outside the immediate location of the research site vie technology.
1. Curebase Partners with Persephone Biosciences
Curebase teams up with Persephone Biosciences in decentralized clinical colorectal cancer trials. The reason for this partnership revolves around the search for methods of prevention and treatment of said disease using decentralized clinical trials, or DCT’s. Here, technology is utilized so those conducting the trials can do them in person or remotely. Options are explored which allow the researchers to team up to find answers while not being in the same space. Thus proving that by bringing brilliant minds together from all over the world via technology can help reach conclusions faster.
2. Curebase teams up with Blue Note Therapeutics
Curebase teams up with Blue Note Therapeutics in order to assist cancer patients in managing their health. Blue Note Therapeutics is a Prescription Digital Therapeutics or PDT company that works to ease the pain and suffering of cancer patients. The two companies engaged in a virtual clinical trial of two digital therapeutics. This trial is completely remote and will help to study the effectiveness of dealing with patients who cannot leave their homes for whatever reason. According to Geoffrey Eich, Blue Note CEO, “Patients living with cancer frequently experience stress, anxiety, and depression. For many, these symptoms have heightened during the COVID-19 pandemic with healthcare restrictions and disruptions in cancer care,” Our collaboration with Curebase is exciting as it brings together our unique capabilities to expand our reach in recruiting for this new, fully virtual clinical trial.”
3. Curebase is a Champion of Decentralized Clinical Trials
We learned a lot from the COVID lockdowns. One of which is the importance of virtual medicine or telemedicine. With virtual medicine patients who cannot leave their home can still gain access to a physician. Curebase is the champion of decentralized clinical trials. This means that via technology, researchers from all over the world can put their heads together when it comes to clinical trials without being in the same room, so to speak. No matter the location, such virtual research sites can help healthcare professionals and researchers gain insight into learning about illnesses and how to treat them. Quicker results and a greater diversity of subjects are guaranteed.
4. Curebase Receives Honorable Mention
Curebase’s dedication to the advancement of decentralized clinical trials earned it honors in four categories in the Fast Company’s 2022 World Changing Idea Awards. The four honors are as follows: Best World Changing Idea NA, Pandemic Response, Small Business and General Excellence. Fast Companies Awards are all about creativity, innovation and invention. “We are humbled to have been recognized by Fast Company for our efforts to democratize clinical research and bring it to people around the world,” said Curebase founder and CEO. “Everyday people wish for access to new science to help them in their battle against a healthcare foe. It is our mission to allow those people to continue working with their trusted healthcare team, from their home or local providers, and have easy access to cutting-edge clinical research.”
5. Curebase Partners with CoBTek
Curebase and CoBTek joined forces to study how to help the elderly remain autonomous via remote intervention. The subjects in this trial would be from Italy and France. The goal of the research was to find ways where the elderly can remain at home, caring for themselves for as long as possible, before having to enter an extended living facility. “As Europe’s population ages, and access to healthcare becomes more challenging, it is important that we find ways to reduce the cost of interventions designed to keep seniors physically, mentally and socially active,” said a CoBTeK Spokesperson. “Working with Curebase gives us a trial platform that allows us to assess the effectiveness of home-based interventions on our elderly participants.”
6. Built In Announced Curebase Honors
In January of 2022 Built In announce that Curebase was honored in their Top 100 Best Remote-First Companies to Work For in 2022. “I am proud of the culture of trust and collaboration we have built at Curebase,” states Tom Lemberg. “As a remote-first, mission-driven company, we are always striving to ensure voices across the company are heard to help us achieve our goal of putting patients first in clinical research. This recognition is truly a testament to our amazing team and their mission-driven commitment to improve healthcare.”
7. Curebase Joins the WCG Avoca Quality Consortium
December 2021 saw Curebase join the WCG Avoca Quality Consortium along with 175 other companies. The purpose of the consortium is to bring together companies who share the same goal: To improve the standing of clinical trials utilizing various technologies. The more accurate the clinical trial process, the better results for patient health. “As a provider of decentralized clinical trial technologies, we are excited to welcome Curebase as a new AQC Member,” said Michelle Webb, VP of the AQC. “Curebase, along with the other AQC members shine a light on key issues leading to relevant discussions on critical topics in the industry. We believe that collaboration and knowledge sharing are critical to driving essential quality improvements in clinical research.
8. CEO Tom Lemberg’s Philosophy Guides Curebase
Curebase’s CEO Tom Lemberg is the guiding light to the current success enjoyed by Curebase. A graduate of Harvard University with a Bachelors in Arts and Sciences, Tom’s philosophy is to “enable any patient, anywhere to participate in clinical trials.” by exercising this philosophy, Curebase has been able to show the healthcare community the importance of including diverse populations in their research via virtual research sites.
9. Curebase named as One of the Most Innovative Digital Health Startups
The 2022 CB Insights Digital Health 150 named Curebase to its list of the most Innovative Digital Health Startups. The Digital Health 150 is a list which brings to light some of the best, creative and innovative digital health companies around. “Being recognized by CB Insights to their Digital Health 150 list is a testament to the impact we are making in clinical trials right now to power studies that reach more patients everywhere, including at home and with their own doctors,” says Tom Lemberg.
10. Curebase’s DCT Model Guarantees More Diversity
The very model of Curebase’s Decentralized Clinical Trial guarantees diversity in studies. This is due to the remote nature of the model. By using DCT, one can research an illness in one country using subjects from all over the world. Research is no longer tied to location. Clinical research sites are no longer geographically limited, “Recent Curebase studies have shown 61% more diverse populations than the FDA average with 97% patient satisfaction.”
11. Curebase Founder and CEO Featured in Drug Discovery and Development
Clinical trials are used to record the effects certain medications and other therapies have on people. In the past these clinical trials were ruled by location. As such, sample diversity could not be achieved, which left many populations out of the picture. Today, founder and CEO of Curebase have put forth a solution via remote sites. This means that participants who live in another country, or who cannot leave their home, can participate in these decentralized clinical trials. According to Lamberg, “Patients have unique lifestyles, and study designs that cannot accommodate a patient’s needs fail to recruit participants effectively.”
12. Curebase Raises $15 Million for Siteless Trials involving Patient Lifestyles in 2021
Curebase received $15 million in series A funding to engage in siteless trials. Siteless trials involve telehealth, telemedicine and even wearables. This means that the participants will not be physically attending a clinical trial research facility, but are to remain in their own homes (hence, siteless). This virtual clinical trial platform. Funding was led by GGV capital, followed by Bold Capital, Xfund and other funds.
13. Curebase and BYOP Clinical Trials
We’ve already established Curebase as the front runner for the concept of decentralized clinical trials. That being said, they’re not sitting on their laurels and are in a constant state of innovation, and BYOP is another one of these patient-friendly trends. BYOP stands for “Bring Your Own Physician”. You see, one of the reasons patients stay away from participating in clinical trials, is that they are required to ditch the doctor they trust. But with Curebase’s new concept of BYOP, they no longer have to. Here, Tom Lemberg discusses his own sisters journey and why it’s crucial for patients to bring their own physicians.
14. Curebase Partners with LEVEL to Help Veterans Sleep Better
Freedom isn’t free. Indeed, it depends largely on the brave men and women who venture to foreign shores in order to fight for us. As such, we owe these people much. In this case a good nights sleep. Curebase partnered with LEVEL to help make this happen. LEVEL is a cannabis company which devotes itself to cannibas research. “Sleep disruptions can affect everyone’s health and overall quality of life, but the Veteran population in particular is vulnerable,” said Curebase CEO Tom Lemberg. By utilizing the Curebase model of decentralized clinical studies, veterans can be studied in their own homes without traveling to brick and mortar sleep research centers for evaluation
15. Forbes Adds Curebase CEO Tom Lemberg to Their 30 Under 30 list for 2022
Forbes 30 Under 30 List is all about locating the best fresh, young minds who are engaged in making the world a better place. By creating an avenue whereby diverse populations can participate in clinical trials remotely, Lemberg has secured himself a place of high regard in the medical community. No longer do clinical trials have to settle for a local sample of participants. Instead they can involve populations which have been overlooked in the past.
16. Curebase Took the Lockdowns in Stride
According to Adam Samson from Curebase, the COVID-19 lockdowns resulted with Curebase swimming in a sea of new opportunities and higher workload. Their very model of decentralized clinical trials which center on using virtual sites for clinical trials, was a perfect fit during the lockdowns. In fact, Their DCT method had a chance to show its stuff due to the strict lockdown restrictions during COVID-19.
17. Curebase Puts the Patient First
Let’s face it, the world of clinical trials is quite a large one, worth over $50 billion dollars in fact. Traditionally, clinical trials take a while to complete. However, with Curebase’s patient-centric philosophy that’s changing. Their decentralized clinical trial model puts the patient first. By having clinical trials run virtually, almost any patient can participate in them. Patients can now participate in clinical trials without having to visit a brick and mortar clinical testing facility. Instead, the patient can reside at home or live in an entirely different country. This ensures that clinical trials are open for all, diversity is guaranteed, the patient can still retain their own physician and previously under-represented populations can now play a part in the trials.
18. Curebase Joins the SCRS
The SCRS or Society for Clinical Research Sites will now work with Curebase as a Global Impact Partner or GIP. Among its contributions will be to work with the SCRS in helping them to set new research site standards. “Site engagement and access is critical to our mission,” said Tom Lemberg “We are excited to work closely with SCRS as a Global Impact Partner to enable access to clinical studies for any clinician, including independent sites, to advance clinical research.”
19. Total Funding Raised by Curebase is $59 million U.S. Dollars
In May of 2022 Curebase secured another batch of funding, putting its total funding amount raised to $59 million since the firm was established in 2017. With this funding, Curebase intends to continue to evolve its platform. For instance, funding will be used to develop their network of drive-through testing sites, healthcare specialists, physicians and their software. “We’ve proven we are leaders in DCT, but the future isn’t either DCT or traditional – instead it is every study needing to be modern and patient-centric,” That means being able to work with clinics and points of care of all backgrounds.”
20. In Februrary 2022 Curebase Added Two Respected Clinical Trial Experts to Their Advisory Board
In a move made to not only improve the standing of the company but to show the importance of virtual telemedicine, Curebase snagged two of the best professionals in the world of clinical trials, doctors Aaron Kamauu and Amir Lahav to join their team. Since decentralized clinical trials have gained the respect they deserve, these new doctors will help to grow DCT in the international market. According to Dr. Kamauu, “decentralized clinical trials have achieved a level of acceptance and now we’re at the point of iteration and evolution”.
We are rapidly entering a brand new era for all things, such as medicine. The speed, accuracy and efficiency provided the medical community via digital technologies is astounding. Who knows, soon holographic medical personnel will be able to visit patients in their homes one day. Until then, we wait and watch as companies like Curebase work to make digital advancements in telemedicine. Such advancements not only quicken the research and development side of medicine, but also all healthcare workers to place the patients needs first, while accelerating the overall research process. .